

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

FIG. 1

SAHA Patient: IV vs ORAL (200 mg/dose)



# FIG. 2

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)






FIG. 3



# FIG. 4

Protocol 01-021 (ORAL SAHA)  
 ARM A: SOLID TUMOR PATIENTS  
 Cohort I (200 mg/dose)



# FIG. 5






FIG. 6



# FIG. 7

Protocol 01-021  
(ORAL SAHA)  
ARM A: SOLID  
TUMOR PATIENTS  
Cohort IIa (400 mg/dose)





1

SAHA Patients: ORAL/Cohort II (400 mg/dose)

11-OS-400

IV ORAL

12-OS-400

IV ORAL

## Markers

Pre  
2 hrs

Pre

10 hrs

Pre  
2 hrs

Pre

10 hrs

**$\alpha$ -AChH3**

## Stain

01/24/02

12-OS-400

IV

## DAY 1 ORAL

## DAY 21 ORAL

## Markers

Pre

2 hrs

Pre

2 hrs

10 hrs

Pre

2 hrs

9.25 hrs

**$\alpha$ -AChH3**

**stain**

02/15/02





FIG. 9A

Oral 200 mg vs. 400 mg (Fasting)  
Oral dose on Cycle 1 Day 8

# FIG. 9B

Oral 200 mg vs. 400 mg (no-fasting)

Oral Dose on Cycle 1 Day 9



# FIG. 9C

IV 200 mg vs. 400 mg  
IV Dose on Cycle 1 Day 1




FIG. 10

Apparent Half-life of the Oral Dose  
Half-life





FIG. 11

AUC of the Oral  
Dose AUC<sub>last</sub>



## FIG. 12

Bioavailability after 200 and 400 mg by Day





FIG. 13A

CTCL Patient 001 (MD Anderson)

Baseline



After 1 Week of SAHA






FIG. 13B

CTCL Patient 001 (MD Anderson)

Baseline



After 1 Week of SAHA





FIG. 13C

CTCL Patient (MDACC)

Baseline



After 8 weeks of SAHA




FIG. 13D

CTCL Patient 008 (MD Anderson)

Baseline



After 8 weeks of SAHA





FIG. 14

Metastatic Laryngeal Cancer (MSKCC)

Pre-treatment



After 8 weeks of treatment

